摘要
目的 分析13 1I治疗Graves病甲亢的早期疗效及其早发甲低影响因素。方法 对接受13 1I治疗的 34 2例Graves病甲亢患者随访 1年 ,根据是否发生甲低分为第 1组 (甲低组 )与第 2组(无甲低组 ) ;采用SPSS统计软件分析年龄、性别、病程、治疗前甲状腺质量、6h的吸13 1I率与 2 4h的吸13 1I率比值、计划给予每克甲状腺组织的摄取剂量、13 1I剂量、治疗前T4 或T3 水平、是否接受过内科药物治疗等参数与甲低的关系。结果 治疗后 1年 ,有 2 1.2 % (73/ 34 2例 )患者发生甲低 ,有 70 .9%(2 42 / 34 2例 )患者甲状腺功能恢复正常。两组的13 1I剂量间差异无显著性 (t=1.0 45 ,P >0 .0 5 ) ,但每克组织给予的摄取剂量间差异有显著性 (t=2 .696,P <0 .0 5 )。结论 早发甲低与甲状腺质量及给予的每克组织实际摄取13 1I剂量有关 ;只要13 1I治疗前停用内科药物治疗适当时间 ,13
Objective This is a retrospective study designed to evaluate the early therapeutic outcome of radioiodine therapy in patients with Graves' disease and determine whether the outcome of radioiodine therapy in Graves' disease depends on thyroid volume, function, thyreostasis, therapeutic dosage, 131 I uptake, age, sex, and absorbed doses by per gram of thyroid tissue. Methods One year after treatment, 342 patients were divided into two groups according to whether there was hypothyroidism. t test and χ 2 test were used to compare the variable parameters between the two groups. Results 92.1% were cured with a single dose of 131 I , and 21.2% contracted hypothyroidism at 12 months after treatment. The outcome of treatment at 12 months depended on the volume of thyroid and the absorbed doses by per gram of thyroid tissue. And pretreatment with thyreostasis did not reduce the therapeutic efficacy of 131 I in hyperthyroidism if antithyroid drugs were discontinued at least 3 days before 131 I treatment. Conclusions Since most hypothyroidism occured in patients whose thyroid volume is small, appropriate reduction of target dose is recommended here for those patients.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2001年第4期238-239,共2页
Chinese Journal of Nuclear Medicine
